Evaluating the Cerebrospinal Fluid CtDNA Detection by Next-generation Sequencing in the Diagnosis of Meningeal Carcinomatosis

Overview

Journal BMC Neurol

Publisher Biomed Central

Specialty Neurology

Date 2019 Dec 21

PMID 31856745

Citations 25

Authors

Yue Zhao

Jun-Ying He

Yue-Li Zou

Xiao-Su Guo

Jun-Zhao Cui

Li Guo

Hui Bu

Affiliations

Soon will be listed here.

Abstract

Background: Meningeal carcinomatosis (MC) is the most severe form of brain metastasis and causes significant morbidity and mortality. Currently, the diagnosis of MC is routinely confirmed on the basis of clinical manifestation, positive cerebrospinal fluid (CSF) cytology, and/or neuroimaging features. However, negative rate of CSF cytology and neuroimaging findings often result in a failure to diagnose MC from the patients who actually have the disease. Here we evaluate the CSF circulating tumor DNA (ctDNA) in the diagnosis of MC.

Methods: A total of 35 CSF samples were collected from 35 patients with MC for CSF cytology examination, CSF ctDNA extraction and cancer-associated gene mutations detection by next-generation sequencing (NGS) at the same time.

Results: The most frequent primary tumor in this study was lung cancer (26/35, 74%), followed by gastric cancer (2/35, 6%), breast cancer (2/35, 6%), prostatic cancer (1/35, 3%), parotid gland carcinoma (1/35, 3%) and lymphoma (1/35, 3%) while no primary tumor could be found in the remaining 2 patients in spite of using various inspection methods. Twenty-five CSF samples (25/35; 71%) were found neoplastic cells in CSF cytology examination while all of the 35 CSF samples (35/35; 100%) were revealed having detectable ctDNA in which cancer-associated gene mutations were detected. All of 35 patients with MC in the study underwent contrast-enhanced brain MRI and/or CT and 22 neuroimaging features (22/35; 63%) were consistent with MC. The sensitivity of the neuroimaging was 88% (95% confidence intervals [95% CI], 75 to 100) (p = 22/25) and 63% (95% CI, 47 to 79) (p = 22/35) compared to those of CSF cytology and CSF ctDNA, respectively. The sensitivity of the CSF cytology was 71% (95% CI, 56 to 86) (n = 25/35) compared to that of CSF ctDNA.

Conclusions: This study suggests a higher sensitivity of CSF ctDNA than those of CSF cytology and neuroimaging findings. We find cancer-associated gene mutations in ctDNA from CSF of patients with MC at 100% of our cohort, and utilizing CSF ctDNA as liquid biopsy technology based on the detection of cancer-associated gene mutations may give additional information to diagnose MC with negative CSF cytology and/or negative neuroimaging findings.

Citing Articles

Longitudinal CSF Tumor Cell Enumeration and Mutational Analysis as a Driver for Leptomeningeal Disease Management.

Tripathy A, Corkos P, Blouw B, Montgomery D, Moore M, Hedrick M Cancers (Basel). 2025; 17(5).

PMID: 40075672 PMC: 11899081. DOI: 10.3390/cancers17050825.

Next-generation sequencing of circulating tumor DNA in cerebrospinal fluid for detecting gene mutations in central nervous system lymphoma patients.

Fu H, Wang T, Yang Y, Qiu C, Wang H, Qiu Y Ther Adv Hematol. 2025; 16:20406207251321721.

PMID: 40008179 PMC: 11851744. DOI: 10.1177/20406207251321721.

Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastases.

Li L, Huang Z, Chen Y, Ma H, Chen X, Yan H Heliyon. 2025; 10(24):e40703.

PMID: 39759323 PMC: 11696667. DOI: 10.1016/j.heliyon.2024.e40703.

Cerebral spinal fluid analyses and therapeutic implications for leptomeningeal metastatic disease.

Zhu J, Shum M, Qazi M, Sahgal A, Das S, Dankner M J Neurooncol. 2024; 172(1):31-40.

PMID: 39704899 DOI: 10.1007/s11060-024-04902-0.

Applications of cerebrospinal fluid circulating tumor cells and circulating tumor-derived DNA in diagnosis, prognosis, and personalized treatment of CNS metastases.

Pentsova E Front Oncol. 2024; 14:1409383.

PMID: 39403339 PMC: 11471434. DOI: 10.3389/fonc.2024.1409383.

References

Canzoniero J, Park B . Use of cell free DNA in breast oncology. Biochim Biophys Acta. 2016; 1865(2):266-74. DOI: 10.1016/j.bbcan.2016.03.006. View

de Azevedo C, Cruz M, Chinen L, Peres S, Peterlevitz M, Pereira A . Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. J Neurooncol. 2011; 104(2):565-72. DOI: 10.1007/s11060-010-0524-y. View

Cai X, Sheng J, Tang C, Nandakumar V, Ye H, Ji H . Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing. PLoS One. 2014; 9(4):e95228. PMC: 3997391. DOI: 10.1371/journal.pone.0095228. View

Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S . Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005; 102(45):16368-73. PMC: 1283450. DOI: 10.1073/pnas.0507904102. View

De Mattos-Arruda L, Mayor R, Ng C, Weigelt B, Martinez-Ricarte F, Torrejon D . Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015; 6:8839. PMC: 5426516. DOI: 10.1038/ncomms9839. View

Orphanos G, Ioannidis G, Michael M, Kitrou G . Prostate-specific antigen in the cerebrospinal fluid: a marker of local disease. Med Oncol. 2008; 26(2):143-6. DOI: 10.1007/s12032-008-9096-5. View

Piccioni D, Singh Achrol A, Kiedrowski L, Banks K, Boucher N, Barkhoudarian G . Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. CNS Oncol. 2019; 8(2):CNS34. PMC: 6713031. DOI: 10.2217/cns-2018-0015. View

Diaz Jr L, Williams R, Wu J, Kinde I, Hecht J, Berlin J . The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012; 486(7404):537-40. PMC: 3436069. DOI: 10.1038/nature11219. View

Martins S, de Azevedo C, Chinen L, Cruz M, Peterlevitz M, Gimenes D . Meningeal carcinomatosis in solid tumors. Arq Neuropsiquiatr. 2012; 69(6):973-80. DOI: 10.1590/s0004-282x2011000700024. View

10.

Chamberlain M, Glantz M, Groves M, Wilson W . Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol. 2009; 36(4 Suppl 2):S35-45. DOI: 10.1053/j.seminoncol.2009.05.005. View

11.

Gauchez A, Pez E, Boutonnat J, Bourre J, Pelletier L, Payan R . [Early detection of leptomeningeal metastasis in patients with metastatic breast carcinoma: validation of CA 15-3 measurement in cerebrospinal fluid]. Ann Biol Clin (Paris). 2007; 65(6):653-8. View

12.

Stockhammer G, Poewe W, Burgstaller S, Deisenhammer F, Muigg A, Kiechl S . Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology. 2000; 54(8):1670-6. DOI: 10.1212/wnl.54.8.1670. View

13.

Corro C, Hejhal T, Poyet C, Sulser T, Hermanns T, Winder T . Detecting circulating tumor DNA in renal cancer: An open challenge. Exp Mol Pathol. 2017; 102(2):255-261. DOI: 10.1016/j.yexmp.2017.02.009. View

14.

Calapre L, Warburton L, Millward M, Ziman M, Gray E . Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Lett. 2017; 404:62-69. DOI: 10.1016/j.canlet.2017.06.030. View

15.

Newman A, Bratman S, To J, Wynne J, Eclov N, Modlin L . An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014; 20(5):548-54. PMC: 4016134. DOI: 10.1038/nm.3519. View

16.

Freilich R, Krol G, DeAngelis L . Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995; 38(1):51-7. DOI: 10.1002/ana.410380111. View

17.

Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Agrawal N . Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224):224ra24. PMC: 4017867. DOI: 10.1126/scitranslmed.3007094. View

18.

Chamberlain M . Neoplastic meningitis. Curr Neurol Neurosci Rep. 2008; 8(3):249-58. DOI: 10.1007/s11910-008-0038-6. View

19.

Wang Y, Springer S, Zhang M, McMahon K, Kinde I, Dobbyn L . Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A. 2015; 112(31):9704-9. PMC: 4534284. DOI: 10.1073/pnas.1511694112. View

20.

Rhodes C, Glantz M, Glantz L, Lekos A, SORENSON G, Honsinger C . A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer. 1996; 77(3):543-8. DOI: 10.1002/(SICI)1097-0142(19960201)77:3<543::AID-CNCR17>3.0.CO;2-4. View